Clinical Trials Logo
  1. Home
  2. Migraine With or Without Aura
  3. NCT01978496

Efficacy, Safety, and Tolerability of Oral Eletriptan for Treatment of Acute Migraine

Migraine With or Without Aura Clinical Trial

Official title:
A Multicenter Double-blind, Randomized Placebo Controlled, Parallel Group, Study of the Efficacy and Safety of Oral Eletriptan in Subjects With Acute Migraine

Clinical Trial Summary

To confirm the efficacy of three dose levels of oral eletriptan relative to placebo in relieving symptoms of acute migraine and to further explore the dose response relationship of eletriptan.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01978496
Study type Interventional
Source Pfizer
Contact
Status Completed
Phase Phase 3
Start date July 1996
Completion date December 1997
View Details
See also
  Status Clinical Trial Phase
Completed NCT00792636 - A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period Phase 4
Completed NCT00383162 - A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2) Phase 3
Completed NCT01986088 - Eletriptan vs Sumatriptan: A Double-blind, Placebo-controlled, Multiple Migraine Attack Study Phase 3
Completed NCT02605174 - Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine Phase 3
Completed NCT01989936 - Eletriptan for the Treatment of Migraine in Patients With Previous Poor Response or Tolerance to Oral Sumatriptan Phase 3
Completed NCT06245902 - An Acute Migraine Factorial Study Phase 2
Completed NCT03061734 - Low-Dose Naltrexone and Acetaminophen Combination and Its Components in the Acute Treatment of Migraine Phase 2
Completed NCT00382993 - A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2) Phase 3
Completed NCT01986270 - Comparative Study of Oral Eletriptan (40mg and 80mg), Oral Sumatriptan (25mg and 50mg) and Placebo Phase 3
Completed NCT03194555 - The Preventive Treatment of Migraine With Low-Dose Naltrexone and Acetaminophen Combination Phase 2